Companies tracker — Levin lab ecosystem
Research, not investment advice. This page tracks organizations publicly tied to Michael Levin and his lab so we can follow how the science is being commercialized. Nothing here is a recommendation to buy, sell or invest. Private-company funding figures come from company statements and third-party databases and may be incomplete. Every link was checked on 2026-10-15.
Status at a glance (2026-10-15): none of the companies below is publicly traded. There is no public stock that gives direct exposure to Levin's work today. Paths that exist in principle are private (venture funds, private rounds, usually for accredited investors) — see "Ways to get exposure" at the bottom.
Levin himself discloses licensing: in Life, Machines, and a Foundation for Synthbiosis he mentions three disclosures of companies that licensed the lab's technology, and in Biology, AI, and Diverse Intelligence he says "There's four companies that have licensed some of the work." In Thoughts as Thinkers (2026-10-31) he says "there are uh three or four companies that have now licensed some of our" inventions. His lab site lists Unravel Biosciences, Morphoceuticals and Fauna Systems among his affiliations (drmichaellevin.org).
Spinouts and co-founded companies
| Company | Levin's role | What it does | Status | Funding (public info) | Sources |
|---|---|---|---|---|---|
| Morphoceuticals, Inc. (Medford / Marblehead, MA) | Scientific co-founder and advisor (with David Kaplan, Tufts Engineering) | Bioelectric "morphoceutical" drugs for regeneration; built on the 2022 adult frog limb-regeneration work; describes a proprietary atlas of the "bioelectrome" | Private, seed stage. CEO Jim Jenson (since Apr 2024); board chair Roger Pomerantz, MD (Jul 2025) | Says it has raised more than $15M in seed, led initially by Juvenescence and Prime Movers Lab; in 2025 said it was seeking a $10M bridge. Ferocity Capital named as an investor (Jan 2026) | Levin bio · Jul 2025 release · CEO interview |
| Fauna Systems Inc. (Cambridge, MA; Delaware corp., 2021) | Co-founder (with Josh Bongard, UVM) | Commercial xenobots ("biobots") designed with AI; targets include pollutant detection/cleanup and health uses; "Mombot" design system | Private, early stage. Co-founded with Hyperbolic Holdings | SEC Form D (Mar 2025): $1.96M raised of a $2.5M debt round | About · People · Hyperbolic news · Form D summary |
| Unravel Biosciences (Boston) | Co-founder and advisor | Drug discovery for complex diseases (lead: Rett syndrome) using tadpole behavior screens that began as a Levin–Wyss collaboration (CogniXense → BioNAV platform) | Private; spun out of Harvard's Wyss Institute in 2021, licensing technology from Harvard and Tufts | Seed investors include RTK Group (2022); database figures vary | About · Wyss license news · CogniXense · RTK release |
| Astonishing Labs | Scientific co-founder and advisor; "our first Astonishing Labs scientist" | Venture-creation fund that builds companies from university science; portfolio lists Anthrobots, Inc. and Cellja Vu, Inc. | Private fund (co-founders include Jess Mah; managing partner Tom Cirrito) | Not disclosed | Home · Team |
Funders of the lab (non-investable, but signal where conviction is)
| Funder | What they funded | Source |
|---|---|---|
| Paul G. Allen Frontiers Group | The Allen Discovery Center at Tufts ("Reading and Writing the Morphogenetic Code"), announced 2016; up to $30M over eight years in total scope | Tufts Now |
| Templeton World Charity Foundation | $3.92M, "Re-training Molecular Networks" (learning in gene regulatory networks, toward cancer and regeneration) | TWCF project 0606 |
| John Templeton Foundation | $2.13M, "Synthetic Living Machines and the Emergence of Purpose" (reported by Tufts Arts & Sciences grants list) | Tufts A&S major grants page (blocks automated checks; confirm manually) |
Investors in the spinouts that are themselves organizations to watch: Juvenescence (longevity company/investor, private), Prime Movers Lab (site, venture firm), Ferocity Capital, RTK Group, Hyperbolic Holdings.
Ways to get exposure (research notes, not advice)
- No public market route today. None of these companies trades on an exchange. Watch for: an IPO, an acquisition by a public pharma company, or a public company licensing Tufts bioelectric patents.
- Private rounds. Morphoceuticals has said publicly it is raising. Private rounds are generally limited to accredited investors and are high-risk and illiquid.
- Venture funds. Astonishing Labs and Prime Movers Lab are the funds closest to Levin's work; LP access is typically restricted.
- Equity crowdfunding. None of these companies has a public Reg CF campaign that we found as of 2026-10-15. Re-check quarterly.
Open questions to research next
- Which is the "fourth" licensee Levin mentions? Candidates: Anthrobots, Inc. or Cellja Vu, Inc. (Astonishing Labs portfolio) — unconfirmed.
- Tufts and Harvard patent filings on bioelectric control of regeneration and cancer: who holds licenses?
- Public companies working on bioelectric or electroceutical medicine adjacent to (but not tied to) Levin — keep in a separate "adjacent" list so ties are never overstated.
Related
Michael Levin · Bioelectricity · Regeneration and anatomical memory · Xenobots and anthrobots · What's new